MedTrace Logo

Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC

NCT00865475 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2013-09-12

No results posted yet for this study

Summary

The aim of this study is to measure the prevention of lipoatrophy in patients treated with Lopinavir/R in monotherapy versus ZDV + 3TC + ABC

Conditions

  • HIV Infection
  • HIV Infections

Interventions

DRUG

AZT+3TC+ABV (Trizivir)

Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy

DRUG

Switching to LPV/r monotherapy (Kaletra)

Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Fundacion SEIMC-GESIDA

    lead OTHER

Principal Investigators

  • Jose Antonio Iribarren · Hospital de Donostia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00865475 on ClinicalTrials.gov